Navigation Links
New Research Study Seeks Improved Quality of Life for People in the Future with Schizophrenia
Date:8/26/2008

Miranda Chakos, MD of SUNY Downstate Medical Center leads research for local patients

Brooklyn, NY (PRWEB) August 26, 2008 -- Imagine going through the day without the ability to concentrate and focus on the things you enjoy and important tasks that you need to complete. Think what it would be like, struggling to remember what you just talked about or learned a short time ago. Consider how you would feel if you couldn't even accomplish simple tasks, such as making a phone call, grocery shopping or scheduling an appointment.

We all have challenging moments . . . but for people suffering from schizophrenia, these frustrations are a way of life, virtually every day. People with schizophrenia struggle to concentrate, remember and learn. These deficits associated with the thinking process are called cognitive impairments, making it difficult to accomplish the demands of everyday life, both big and small.

Managing the demands of daily life is made easier when individuals with schizophrenia maintain a stable regimen of medication -- even more so for those with trusted family members or caregivers to help oversee the individual's personal affairs and coordinate care. Despite the challenges, most people with schizophrenia and their caregivers are searching for a better quality of life.

Fortunately, there is hope, thanks to a new https://www.cognitivestudy.com/whatToExpect.php [investigational drug research study] now underway in the Brooklyn, NY area. The primary goal of this study is to evaluate the safety and effectiveness of an investigational drug in improving cognitive functioning for people with schizophrenia, using a new evaluation tool called https://www.cognitivestudy.com/additionalResources.php [MATRICS] (Measurement and Treatment Research to Improve Cognition in Schizophrenia). This study is unique because participants are not required to change their already-stable medication regimen. Rather, the new investigational medication is added to their currently established treatment.

Candidates for this study must be 18 to 65 years old, diagnosed with schizophrenia at or before age 35 and currently taking one of five medications for schizophrenia which include olanzapine, risperidone/paliperidone, quetiapine or aripiprazole. Participants must also be considered outpatient (living in the community). https://www.cognitivestudy.com/faq.php [Qualified study participants] will receive all investigational medication and study-related care at no cost, and may also receive compensation for travel.

Miranda Chakos, MD of SUNY Downstate Medical Center seeks participants for this new study. If you or someone you know suffers from schizophrenia, please contact us for additional information at 888.988.6736. Further details about the study are also available at http://www.cognitivestudy.com.

Contact:
Hal Coxon
Axiom Accelerated Clinical Patient Recruitment
(847) 919-1005
halcoxon@axmarketing.com
http://www.cognitivestudy.com

# # #

Read the full story at http://www.prweb.com/releases/medical_study/schizophrenia/prweb1241444.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Research finds Americas elderly suffering abuse
2. Operations research promises continued gains for HIV treatment in resource-limited countries
3. SNM and ASTRO team up to advance molecular imaging and cancer research
4. CytoViva(R) Introduces Breakthrough Nano-Technology Research Tool
5. The Brain Aneurysm Foundation Announces 2008 Research Grant Recipients
6. Reeve Foundation Recruits Distinguished Stem-Cell Neurobiologist - The Salk Institutes Samuel L. Pfaff, Ph.D. - to its International Research Consortium
7. UTMB researchers test new vaccine to fight multiple influenza strains
8. AIAM Sponsors Leading Child Safety Research Initiative
9. UNC researcher aims to unmask cancer cells to trigger bodys immune system
10. STEMCELL Technologies Introduces AggreWell™400 for Standardized Embryonic Stem Cell and Induced Pluripotent Stem Cell Research
11. UCSF faculty receive $13.7M from CIRM for stem cell research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... DC (PRWEB) , ... March 30, 2017 , ... ... and organizations submitted a letter to President Trump expressing their support for an ... medical doctors, two Ph.D. scientists and one medical journalist, will hold a press ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, ... each year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, ... efforts focus on finding more effective treatment options, the San Diego Gamma Knife ...
(Date:3/29/2017)... ... ... the main cause of hay fever in the United States, with an estimated 95 percent ... to July each year; with the worst time for sufferers being June and July. ... ) provide an effective defense against grass pollen; they are proven in independent studies to ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its founder, Kathy Heshelow, are ... it has been used for thousands of years. , "The West has caught on, ... " Turmeric: How to Use it For Your Wellness. Overcome Inflammation, Enemy of the ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, ... Stores in two southeastern states. Ingredients in HeartBoost, an over the counter heart ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets ... Market Size & Forecast By Type (Insource IONM, Outsource IONM), ... report to their offering. ... The global Intraoperative Neuromonitoring (IONM) market ... intraoperative neuromonitoring market is anticipated to witness significant growth in ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Global ... ... aesthetic devices market to grow at a CAGR of 8.12% during ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:3/29/2017)... 29, 2017 Avelas Biosciences, Inc., a clinical stage oncology-focused ... today announced that Carmine N. Stengone , president and chief ... Needham & Company 16 th Annual Healthcare Conference on Wednesday, ... the Westin Grand Central Hotel in New York City ... ...
Breaking Medicine Technology: